



April 25, 2022

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Growth Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8046
URL: <https://solasia.co.jp/en/>

Solasia's Partner, Isofol announced start of study data analysis
of SP-05 (arfolitixorin) phase III AGENT study

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the start of data analysis of the multi-center, global Phase III AGENT Study investigating arfolitixorin in combination with 5-FU, oxaliplatin and bevacizumab in advanced, metastatic colorectal cancer (mCRC).

For more information, please refer to the Isofol's website.
<https://isofolmedical.com/>

###